Abstract
Semaglutide for type 2 diabetes control in metabolic dysfunction-associated steatotic liver disease (MASLD): a two-way effect?
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have